Rare disease registries for certain lysosomal storage disorders, including, but not limited to, Fabry, Gaucher, MPS I, and Pompe diseases (each, a Registry)
The Rare Disease Registry Program (including but not limited to, Gaucher, Fabry, MPS I, and Pompe diseases) is a multi-center, international, longitudinal, observational program that tracks the natural history and outcomes of patients with these rare diseases.
Protocol Number: Rare Disease Registry
Design:
The Registry program is a multi-center, international, observational program for patients with these rare diseases that was designed to track the natural history and outcomes of patients. No experimental intervention is given; thus, a patient will undergo clinical assessments and receive standard of-care treatment as determined by the patient’s physician. As the Registries are a voluntary program, the total number of patients with these diseases who will participate in the Registries and the associated person-years of follow-up are not pre-defined, as not all patients have been identified, nor will all patients wish to participate. The Registry databases have been designed to collect a variety of baseline and follow-up data obtained through routine clinical and laboratory assessments. All data submission is voluntary and there are no pre-determined follow-up periods. Participating sites are encouraged to enter comprehensive baseline data at enrollment and to perform follow-up assessments at regular intervals. While the protocols provide Recommended Schedules of Assessments, each physician is solely responsible for determining the appropriate clinical care for each patient.
Condition | Fabry Disease |
---|---|
Clinical Study Identifier | TX141086 |
Sponsor | Genzyme |
Last Modified on | 23 November 2020 |
,
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreEvery year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.